Changes in prescribing patterns and clinical outcomes in elderly diabetic patients in 2000 and 2010: Analysis of a large Italian population-based study

European Journal of Clinical Pharmacology

Volumn 70, Issue 8, 2014, Pages 965-974

  Baviera, Marta ^a   Cortesi, Laura ^a   Tettamanti, Mauro ^a   Avanzini, Fausto ^a   Marelli, Giuseppe ^b   Marzona, Irene ^a   Nobili, Alessandro ^a   Riva, Emma ^a   Fortino, Ida ^c   Bortolotti, Angela ^c   Merlino, Luca ^c   Roncaglioni, Maria Carla ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b DESIO HOSPITAL   (Italy)

^c Regional Health Ministry   (Italy)

Author keywords

Diabetes; Elderly; Hospital admission; Mortality; Prescriptions

Indexed keywords

AGED; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG UTILIZATION; EPIDEMIOLOGY; FEMALE; HOSPITALIZATION; HUMAN; ITALY; MALE; MORTALITY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS; DRUG UTILIZATION; FEMALE; HOSPITALIZATION; HUMANS; ITALY; MALE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84905085596     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1678-x     Document Type: Article

References (46)

1. Sue Kirkman M, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, Huang ES, Korytkowski MT, Munshi MN, Odegard PS, Pratley RE, Swift CS (2012) Diabetes in older adults: a consensus report. J Am Geriat Soc 60(12):2342-2356
2. Brown AF, Mangione CM, Saliba D, Sarkisian CA, California Health care Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes (2003) Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriat Soc 51(Suppl 9):S265-S280 (Pubitemid 36535105)
3. Cruz-Jentoft AJ, Carpena-Ruiz M, Montero-Errasquín B, Sánchez-Castellano C, Sánchez-García E (2013) Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. J Am Geriat Soc 61(5):734-738
4. Pozzilli P, Leslie RD, Chan J, De Fronzo R, Monnier L, Raz I, Del Prato S (2010) The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 26(4):239-244
5. Del Prato S, LaSalle J, Matthaei S, Bailey CJ, Global Partnership for Effective Diabetes Management (2010) Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 64(3):295-304
6. Gómez Huelgas R, Díez-Espino J, Formiga F, Lafita Tejedor J, Rodríguez Mañas L, González-Sarmiento E, Menéndez E, Sangrós J, en nombre del Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el anciano (2013) Tratamiento de la diabetes tipo 2 en el pacienteanciano. Med Clin (Barc) 140(3):134.e1-134.e12
7. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545-2559
8. Greenfield S, Billimek J, Pellegrini F, Franciosi M, De Berardis G, Nicolucci A, Kaplan SH (2009) Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes. A cohort study. Ann Intern Med 151(12):854-860
9. Tschöpe D, Bramlage P, Binz C, Krekler M, Plate T, Deeg E, Gitt AK (2011) Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients - an analysis of the DiaRegis registry. Cardiovasc Diabetol 10:66. doi:10.1186/1475-2840-10-66
10. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR (2008) Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia. Diabetes Care 31(11):2086-2091
11. Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschöpe D (2012) Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol 11:22. doi:10.1186/1475-2840-11-22
12. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association; European Association for Study of Diabetes (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1):193-203
13. Stahl M, Berger W (1999) Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 16(7):586-590
14. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, RECORD Study Team (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicenter, randomized, open-label trial. Lancet 373(9681):2125-2135
15. Koro CE, Qinggong F, Stender M (2008) An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. Pharmacoepidemol Drug Saf 17(10): 989-996
16. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA 298(10): 1180-1188 (Pubitemid 47403104)
17. Misbin RI (2005) Evaluating the safety of diabetes drugs. Perspective of a food and drug administration insider. Diabetes Care 28(10): 2573-2576
18. Franchi C, Tettamanti M, Pasina L, Djignefa CD, Fortino I, Bortolotti A, Merlino L, Nobili (2014) A. Changes in drug prescribing to Italian community-dwelling elderly people: the EPIFARM-Elderly Project 2000-2010. Eur J Clin Pharmacol. doi:10.1007/s00228-013-1621-6
19. American Diabetes Association (2008) Standards of medical care in diabetes. Diabetes Care 31(1):S12-S54
20. Associazione Medici Diabetologi (AMD), Società Italiana di Diabetologia (SID) (2010) Standard Italiani per la Cura del Diabete Mellito 2009-2010. Linee Guida e Raccomandazioni. Infomedica Srl, Turin
21. CINECA Osservatorio ARNO Diabete-Il profilo assistenziale della popolazione con diabete Rapporto 2011, vol XVII. Available at: https://osservatorioarno.cineca.org/ Accessed 9 Jan 2014
22. L'uso dei farmaci in Italia - Rapporto Nazionale anno 2012, September 2013. Available at: http://www.agenziafarmaco.gov.it/it/content/osservatorio- sull%E2%80%99impiego-dei-medicinaliosmed Accessed 2 Dec 2013
23. Leal I, Romio SA, Schuemie M, Oteri A, Sturkenboom M, Trifirò (2012) G. Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone. Br J Clin Pharmacol 75(3):861-868
24. Cohen A, Rabbani A, Shah N, Alexander GC (2010) Changes in glitazone use among office-based physicians in the U.S., 2003-2009. Diabetes Care 33(4):823-825
25. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA, Choudhry NK (2012) Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 125(3):302e1-302e7
26. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/000268/human-med-000662.jsp&mid=WC0b01ac058001d124 Accessed 2 Dec 2013
27. Baviera M, Monesi L, Marzona I, Avanzini F, Monesi G, Nobili A, Tettamanti M, Riva E, Cortesi L, Bortolotti A, Fortino I, Merlino L, Fontana G, Roncaglioni MC (2011) Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: a large population-based study. Diabetes Res Clin Pract 93(1):123-130
28. Sheehan MT (2003) Current therapeutic options in type 2 diabetes mellitus: a practical approach. Clin Med Res 1(3):189-200
29. Richard KR, Shelburne JS, Kirk JK (2001) Tolerability of dipeptidyl peptidase-4 inhibitors: a review. ClinTher 33(11):1609-1629
30. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W (2011) Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 13(10):947-954
31. Monami M, Iacomelli I, Marchionni N, Mannucci E (2010) Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 20(4):224-235
32. Tschöpe D, Hanefeld M, Meier JJ, Gitt AK, Halle M, Bramlage P, Schumm-Draeger PM (2013) The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes. Cardiovasc Diabetol 12:62. doi:10.1186/1475-2840-12-62
33. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560-2572
34. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, Investigators VADT (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl JMed 360(2):129-139
35. Parabiaghi A, Franchi C, Tettamanti M, Barbato A, D'Avanzo B, Fortino I, Bortolotti A, Merlino L, Nobili A (2011) Antidepressants utilization among elderly in Lombardy from 2000 to 2007: dispensing trends and appropriateness. Eur J Clin Pharmacol 67(10):1077-1083
36. Castelpietra G, Morsanutto A, Pascolo-Fabrici E, Isacsson G (2008) Antidepressant use and suicide prevention: a prescription database study in the region Friuli Venezia Giulia, Italy. Acta Psychiatr Scand 118:382-388
37. Kivimäki M, Batty GD (2012) Antidepressant drug use and future diabetes risk. Diabetologia 55(1):10-12
38. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360(9346):1623-1630 (Pubitemid 35379733)
39. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicenter randomized placebo-controlled trial. Lancet 364(9435):685-696 (Pubitemid 39140624)
40. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Trialists' Treatment (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267-1278
41. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV (2009) Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301(15):1565-1572
42. Yaffe K, Falvey CM, Hamilton N, Harris TB, Simonsick EM, Strotmeyer ES, Shorr RI, Metti A, Schwartz AV, Health ABC Study (2013) Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med 173(14):1300-1306
43. Van Bruggen R, Gorter K, Stolk RP, Zuithoff P, Klungel OH, Rutten GE (2009) Refill adherence and polypharmacy among patients with type 2 diabetes in general practice. Pharmacoepidemiol Drug Saf 18(11):983-991
44. Støvring H, Andersen M, Beck-Nielsen H, Green A, Vach W (2007) Counting drugs to understand disease: the case of measuring the diabetes epidemic. Popul Health Metr 5:2
45. Bruno G, LaPorte RE, Merletti F, Biggeri A, McCarty D, Pagano G (1994) National diabetes programs. Application of capture-recapture to count diabetes? Diabetes Care 17(6):548-556 (Pubitemid 24161976)
46. Brilleman SL, Salisbury C (2013) Comparing measures of multimorbidity to predict outcomes in primary care: a cross sectional study. Fam Pract 30(2):172-178